CN102698064A - 一种治疗更年期综合征的药剂 - Google Patents
一种治疗更年期综合征的药剂 Download PDFInfo
- Publication number
- CN102698064A CN102698064A CN2012101931177A CN201210193117A CN102698064A CN 102698064 A CN102698064 A CN 102698064A CN 2012101931177 A CN2012101931177 A CN 2012101931177A CN 201210193117 A CN201210193117 A CN 201210193117A CN 102698064 A CN102698064 A CN 102698064A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicament
- climacteric syndrome
- radix
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 6
- 241000736246 Pyrola Species 0.000 claims abstract description 3
- 210000000582 semen Anatomy 0.000 claims description 10
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 3
- 241000605447 Anemarrhena Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 240000007185 Albizia julibrissin Species 0.000 abstract 1
- 241000605445 Anemarrhena asphodeloides Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 240000006766 Cornus mas Species 0.000 abstract 1
- 240000007371 Cuscuta campestris Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000008454 Hyperhidrosis Diseases 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- -1 absorption carrier Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗更年期综合征的药剂，它是由下述重量配比的物质制成：山茱萸、麦冬、酸枣仁、淫羊藿、柴胡、黄连、枸杞、菟丝子、知母、茯苓、海浮石、甘草、陈皮、鹿衔草、当归和合欢皮。本发明所述的治疗更年期综合征的药剂的全部成分都是天然材料，安全性较好，效果明确，适于在临床上大规模推广。
Description
技术领域
本发明涉及妇科领域，具体来说涉及一种治疗更年期综合征的药剂。
背景技术
更年期综合征是指妇女从性成熟期逐渐进人老年期的过渡时期。是由于雌激素水平下降所致的植物神经功能紊乱的症状，多发生于45-55岁，临床表现为潮热多汗，心悸失眠，烦躁易怒，月经紊乱或闭经，情志不宁等，严重影响到生活和工作。
发明内容
本发明的目的是提供一种治疗更年期综合征的药剂。
为了实现本发明的目的，本发明提供一种治疗更年期综合征的药剂，它是由下述重量配比的物质制成：山茱萸3-5份、麦冬1-3份、酸枣仁1-3份、淫羊藿2-5份、柴胡0.1-0.5份、黄连1-3份、枸杞2-5份、菟丝子1-3份、知母3-5份、茯苓3-5份、海浮石1-3份、甘草5-8份、陈皮1-3份、鹿衔草1-3份、当归3-5份和合欢皮1-3份。
优选地，本发明所述的治疗更年期综合征的药剂是由下述重量配比的物质制成：山茱萸3份、麦冬2份、酸枣仁3份、淫羊藿2份、柴胡0.3份、黄连2份、枸杞4份、菟丝子2份、知母4份、茯苓3份、海浮石2份、甘草6份、陈皮2份、鹿衔草2份、当归4份和合欢皮1份。
优选地，本发明的药剂可以为片剂、分散片、胶囊剂或汤剂。可以采用本领域技术人员熟知的方法来进行药剂的制备。根据需要，可以加入各种药学上可接受的载体。所述的载体包括药学领域常规的稀释剂、赋形剂、填充剂、粘合剂、湿润剂、崩解剂、吸收促进剂、表面活性剂、吸附载体、润滑剂等。本发明的药剂在制备时，可选择的填充剂有：淀粉、糖粉、磷酸钙、糊精、微晶纤维素、乳糖、预胶化淀粉、甘露醇等；可选择的粘合剂有：羧甲基纤维素钠、PVP-K30、羟丙基纤维素、淀粉浆、甲基纤维素、乙基纤维素、羟丙基甲基纤维素、胶化淀粉等；可选择的崩解剂有：干淀粉、交联聚维酮、交联羧甲基纤维素钠、羧甲基淀粉钠、低取代羟丙基纤维素等；可选择的润滑剂有：硬脂酸镁、滑石粉、十二烷基硫酸钠、微粉硅胶等。
本发明所述的治疗更年期综合征的药剂的全部成分都是天然材料，安全性较好，效果明确，适于在临床上大规模推广。
具体实施方式
下面通过实施例进一步说明本发明。应该理解的是，本发明的实施例是用于说明本发明而不是对本发明的限制。根据本发明的实质对本发明进行的简单改进都属于本发明要求保护的范围。除非另有说明，否则本发明中的百分数是重量百分数。
实施例
称取山茱萸30克、麦冬20克、酸枣仁30克、淫羊藿20克、柴胡3克、黄连20克、枸杞40克、菟丝子20克、知母40克、茯苓30克、海浮石20克、甘草60克、陈皮20克、鹿衔草20克、当归40克和合欢皮10克，粉碎，过80目筛。然后称取糖粉50克，过80目筛，和上述原料混合。用4重量％的HPMC水溶液作粘合剂制软材，制粒(用16目尼龙筛制粒二遍)，在60℃下干燥2-3个小时，用16目的尼龙筛整粒。再加入40克的羧甲基淀粉钠和2克的硬脂酸镁，混匀，用直径14mm的冲头压片100片。
实验例
诊断标准
参照《中医病证诊断疗效标准》中绝经前后诸症诊断依据(国家中医药管理局.中医病证诊断疗效标准[M].第1版.南京：南京大学出版社，1995，66)制定标准：①发病年龄一般在(45-55)周岁绝经前后；②见有月经紊乱，潮热面红，烘热汗出，情绪激动，情志异常，皮肤感觉异常等症。
排除标准
①抑郁症；②原发性高血压、原发性低血压；③慢性贫血者；④心脑血管和泌尿牛殖系统器质性病变者。
选取符合上述诊断标准的患者30例，年龄(45-55)岁，平均(48.7±3.2)岁；病程最短者6个月，最长者3年，平均病程(20.2±13.4)个月。
使用实施例中制备片剂对于上述患者进行治疗，一日两次，每次一片。以30天为一个疗程。
疗效标准及观察指标
参照《中医病证诊断疗效标准》中绝经前后诸症诊断依据的疗效评定标准：①治愈：烘热汗出，情绪激动，情志异常等症状消除；②好转：烘热汗出，情绪激动，情志异常等症状减轻；③未愈：烘热汗出，情绪激动，情志异常等症状无变化。
结果
30例患者经治疗后，观察治疗结果，发现患者的烘热汗出，情绪激动，情志异常等症状消除。由此得出结论，30例患者全部符合治愈标准。
Claims (3)
1.一种治疗更年期综合征的药剂，其特征在于，它是由下述重量配比的物质制成：山茱萸3-5份、麦冬1-3份、酸枣仁1-3份、淫羊藿2-5份、柴胡0.1-0.5份、黄连1-3份、枸杞2-5份、菟丝子1-3份、知母3-5份、茯苓3-5份、海浮石1-3份、甘草5-8份、陈皮1-3份、鹿衔草1-3份、当归3-5份和合欢皮1-3份。
2.根据权利要求1所述的治疗更年期综合征的药剂，其特征在于，它是由下述重量配比的物质制成：山茱萸3份、麦冬2份、酸枣仁3份、淫羊藿2份、柴胡0.3份、黄连2份、枸杞4份、菟丝子2份、知母4份、茯苓3份、海浮石2份、甘草6份、陈皮2份、鹿衔草2份、当归4份和合欢皮1份。
3.根据权利要求1所述的治疗更年期综合征的药剂，其特征在于，所述药剂是片剂、分散片、胶囊剂或汤剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101931177A CN102698064B (zh) | 2012-06-13 | 2012-06-13 | 一种治疗更年期综合征的药剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101931177A CN102698064B (zh) | 2012-06-13 | 2012-06-13 | 一种治疗更年期综合征的药剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102698064A true CN102698064A (zh) | 2012-10-03 |
| CN102698064B CN102698064B (zh) | 2013-08-07 |
Family
ID=46891311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101931177A Expired - Fee Related CN102698064B (zh) | 2012-06-13 | 2012-06-13 | 一种治疗更年期综合征的药剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102698064B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599368A (zh) * | 2013-11-05 | 2014-02-26 | 刘京伟 | 一种治疗更年期高血压的中药制剂 |
| CN104873755B (zh) * | 2015-06-09 | 2018-05-01 | 苏州卫生职业技术学院 | 一种治疗女性更年期综合症的中药组合物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101642504A (zh) * | 2009-06-15 | 2010-02-10 | 张继成 | 补阴清虚热胶囊 |
| CN101869651A (zh) * | 2010-06-04 | 2010-10-27 | 荣成市科学技术情报研究所 | 一种治疗郁症失眠的中药组合物 |
| CN102327243A (zh) * | 2011-09-28 | 2012-01-25 | 海南康芝药业股份有限公司 | 一种匹多莫德咀嚼片 |
-
2012
- 2012-06-13 CN CN2012101931177A patent/CN102698064B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101642504A (zh) * | 2009-06-15 | 2010-02-10 | 张继成 | 补阴清虚热胶囊 |
| CN101869651A (zh) * | 2010-06-04 | 2010-10-27 | 荣成市科学技术情报研究所 | 一种治疗郁症失眠的中药组合物 |
| CN102327243A (zh) * | 2011-09-28 | 2012-01-25 | 海南康芝药业股份有限公司 | 一种匹多莫德咀嚼片 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599368A (zh) * | 2013-11-05 | 2014-02-26 | 刘京伟 | 一种治疗更年期高血压的中药制剂 |
| CN103599368B (zh) * | 2013-11-05 | 2016-02-17 | 刘京伟 | 一种治疗更年期高血压的中药制剂 |
| CN104873755B (zh) * | 2015-06-09 | 2018-05-01 | 苏州卫生职业技术学院 | 一种治疗女性更年期综合症的中药组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102698064B (zh) | 2013-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101584797B (zh) | 一种中药组合物在制备治疗更年期综合征的药物中的应用 | |
| CN105106852A (zh) | 一种治疗乳腺增生及乳腺癌的中药制剂 | |
| CN104666951A (zh) | 一种治疗产后风月子病的中药组合物 | |
| CN102106984B (zh) | 一种用于治疗妊娠恶阻和胎动不安的药物组合物 | |
| CN102657821A (zh) | 一种治疗卵巢囊肿的药剂 | |
| CN102698064B (zh) | 一种治疗更年期综合征的药剂 | |
| CN101628059B (zh) | 一种药物组合物和含有该药物组合物的药物制剂 | |
| CN104524247A (zh) | 一种治疗偏头痛的药物组合物及其用途 | |
| CN104888137B (zh) | 一种治疗多囊卵巢综合症的药物制剂 | |
| CN102274423B (zh) | 一种治疗焦虑症的药剂 | |
| CN106420970A (zh) | 一种治疗卵巢早衰的药物组合物 | |
| CN102657744B (zh) | 一种治疗乳腺炎的药剂 | |
| CN102657752A (zh) | 一种治疗冻疮的药剂 | |
| CN102552511B (zh) | 一种治疗腹泻的药剂 | |
| CN102526473B (zh) | 一种治疗慢性乙型病毒性肝炎的药剂 | |
| CN102133339B (zh) | 一种治疗偏头痛的中药制剂 | |
| CN101934046B (zh) | 一种鹿胎膏及其制备方法 | |
| CN100509019C (zh) | 巴戟胶囊在制备增强免疫药物中的应用 | |
| CN103800736A (zh) | 一种治疗高血压肾病的药物组合物及其应用 | |
| CN104491318A (zh) | 一种治疗哮喘的中药制剂及其制备方法 | |
| CN102266482B (zh) | 一种治疗躁狂症的药剂 | |
| CN102698094A (zh) | 一种治疗女性抑郁症的药剂 | |
| CN115944687B (zh) | 一种改善男性特发性少弱精症的中药组方与一种汤剂和一种片剂 | |
| CN102641418B (zh) | 一种治疗偏头痛的药剂 | |
| CN106943506B (zh) | 一种治疗更年期综合征的药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU XIN NEOLITHIC BASALT FIBER CO., LTD. Free format text: FORMER OWNER: SONG TONGYUN Effective date: 20131202 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 272000 JINING, SHANDONG PROVINCE TO: 213399 CHANGZHOU, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131202 Address after: 213399 Jiangsu city of Changzhou province Liyang Liyang Town of Wuhu Shanghai Road No. 168 Patentee after: Jiangsu Neolith Basalt Fiber Co., Ltd. Address before: 272000 Jining Central Maternal and child health care hospital, No. 135 Jianshe North Road, Shizhong District, Shandong, Jining Patentee before: Song Tongyun |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130807 Termination date: 20150613 |
|
| EXPY | Termination of patent right or utility model |